INSM Insmed Incorporated

$109.33 -2.90%

Data as of Nov 2, 2026 close

Healthcare · Pharmaceutical Preparations

Insmed Incorporated (INSM) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $24.0 billion. Shares last traded at $109.33, 48.6% below their 52-week high. Over the past year the stock is down 43.7%. Net profit margin is -39.9%, below the peer median of -7.6%. Revenue grew 66.7% year over year.

Market Cap

$24.0B

Shares Out

219.4M

EPS (TTM)

-$2.83

P/E (TTM)*

—

P/S Ratio

15.78

P/B Ratio

33.03

Dividend / Share

—

Dividend Yield

—

52-Week High

$212.81

52-Week Low

$90.42

Volume (venue)

151,198

Avg Vol (3m, venue)

182,877.079

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

+17.11%

-1.64%

+10.75%

-21.89%

YTD

-37.19%

-43.74%

Chart

Full chart →

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)

57.15

SMA (50)

$112.37

SMA (200)

$125.20

Price vs SMA50

-2.70%

Price vs SMA200

-12.68%

ATR (14)

$4.57

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue

$1.5B

Net Income

-$606M

Gross Margin

84.4%

Operating Margin

-37.1%

Net Margin

-39.9%

Return on Equity

-83.4%

Return on Assets

-27.2%

Current Ratio

2.86

Debt / Equity

0.75

Revenue Growth (YoY)

+66.7%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-09-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

Period	EPS (diluted)	Reported
Q3 2026	-$0.46	2026-10-29
Q2 2026	-$0.06	2026-08-06
Q1 2026	-$0.76	2026-05-07
Q4 2025 (derived)	-$1.55	2026-02-19
FY 2025	-$6.42	2026-02-19
Q3 2025	-$1.75	2025-10-30

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Pharmaceutical Preparations peers

INSM vs 14 industry peers (Pharmaceutical Preparations), by market cap. Data as of Nov 2, 2026 close

P/S vs peers

15.78 / 7.81 med

+102% premium

Net margin vs peers

-39.9% / -7.6% med

below median

1–14 of 14


LLY	Lilly (Eli)	$1.33T	48.13	15.35	31.9%	-0.28%
JNJ	Johnson & Johnson	$652.2B	40.52	6.57	16.2%	-0.82%
ONC	Beone Medicines Ltd.	$533.8B	814.05	87.09	10.7%	-2.48%
ABBV	AbbVie	$510.3B	80.87	7.93	9.8%	-2.05%
MRK	Merck	$366.4B	115.46	5.50	4.8%	-0.22%
ABT	Abbott Laboratories	$192.1B	30.61	4.26	13.9%	+3.81%
PFE	Pfizer	$175.0B	40.41	2.75	6.8%	+0.69%
VRTX	Vertex Pharmaceuticals	$144.5B	32.80	11.48	35.0%	+1.96%
BMY	Bristol Myers Squibb	$128.8B	13.94	2.58	18.5%	+0.90%
REGN	Regeneron Pharmaceuticals	$99.4B	20.64	5.89	28.5%	+3.63%
TEVA	Teva Pharmaceutical Industries Ltd	$47.4B	67.14	2.74	4.1%	-3.35%
ZTS	Zoetis	$34.4B	13.14	3.61	27.5%	+4.35%
RPRX	Royalty Pharma Plc	$29.6B	36.35	11.68	32.1%	-0.98%
ROIV	Roivant Sciences Ltd.	$25.9B	—	3441.87	—	-2.76%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.